[HTML][HTML] Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant
A Suzuki, H Hara, H Kimura - Neuropharmacology, 2023 - Elsevier
Ketamine exerts rapid and long-lasting antidepressant effects in patients with treatment-
resistant depression. However, its clinical use is limited by its undesirable psychotomimetic …
resistant depression. However, its clinical use is limited by its undesirable psychotomimetic …
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system
S Chaki, M Watanabe - Neuropharmacology, 2023 - Elsevier
The efficacy of currently available medications for depression is unsatisfactory, and that has
spurred the development of novel antidepressants based on a hypothesis other than the …
spurred the development of novel antidepressants based on a hypothesis other than the …
Glutamatergic modulators for major depression from theory to clinical use
RS McIntyre, R Jain - CNS drugs, 2024 - Springer
Major depressive disorder (MDD) is a chronic, burdensome, highly prevalent disease that is
characterized by depressed mood and anhedonia. MDD is especially burdensome as …
characterized by depressed mood and anhedonia. MDD is especially burdensome as …
New therapeutic approaches to inherited metabolic pediatric epilepsies
Treatment options for inherited metabolic epilepsies are rapidly expanding with advances in
molecular biology and the genomic revolution. Traditional dietary and nutrient modification …
molecular biology and the genomic revolution. Traditional dietary and nutrient modification …
Investigational drugs for the treatment of depression (Part 2): Glutamatergic, cholinergic, sestrin modulators, and other agents
O Vasiliu - Frontiers in Pharmacology, 2022 - frontiersin.org
Many investigational drugs with antidepressant activity are currently explored in different
phases of clinical research, with indications such as major depressive disorder, treatment …
phases of clinical research, with indications such as major depressive disorder, treatment …
LT-102, an AMPA receptor potentiator, alleviates depression-like behavior and synaptic plasticity impairments in prefrontal cortex induced by sleep deprivation
Y Zheng, X Yu, L Wei, Q Chen, Y Xu, P Ni… - Journal of Affective …, 2024 - Elsevier
Background Sleep loss is closely related to the onset and development of depression, and
the mechanisms involved may include impaired synaptic plasticity. Considering the …
the mechanisms involved may include impaired synaptic plasticity. Considering the …
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy …
F Dijkstra, P O'Donnell, E Klaassen, D Buhl… - Translational …, 2022 - nature.com
TAK-653 is a novel AMPA receptor positive allosteric modulator in clinical development for
the treatment of major depressive disorder (MDD). This study aimed to measure the …
the treatment of major depressive disorder (MDD). This study aimed to measure the …
Integrin α3 is required for high‐frequency repetitive transcranial magnetic stimulation‐induced glutamatergic synaptic transmission in mice with ischemia
L Liu, H Hu, J Wu, AJ Koleske, H Chen… - CNS Neuroscience …, 2024 - Wiley Online Library
Background Repetitive transcranial magnetic stimulation (rTMS) is an effective therapy in
post‐stroke motor recovery. However, the underlying mechanisms of rTMS regulates long …
post‐stroke motor recovery. However, the underlying mechanisms of rTMS regulates long …
Effects of the selective AMPA modulator NBI‐1065845 on the pharmacokinetics of midazolam or ethinyl estradiol–levonorgestrel in healthy adults
S Lin, A Ionescu, J Maynard‐Scott… - Clinical and …, 2024 - Wiley Online Library
This parallel‐arm, phase I study investigated the potential cytochrome P450 (CYP) 3A
induction effect of NBI‐1065845 (TAK‐653), an investigational α‐amino‐3‐hydroxy‐5 …
induction effect of NBI‐1065845 (TAK‐653), an investigational α‐amino‐3‐hydroxy‐5 …
Comment: Amenable Treatable Severe Pediatric Epilepsies
PL Pearl - Seminars in Pediatric Neurology, 2023 - Elsevier
Amenable Treatable Severe Pediatric Epilepsies Phillip L. Pearl Seminars in Pediatric
Neurology Volume 23, Issue 2, May 2016, Pages 158–166 Vitamin-dependent epilepsies …
Neurology Volume 23, Issue 2, May 2016, Pages 158–166 Vitamin-dependent epilepsies …